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Loss of IL-10 signaling in macrophages limits
bacterial killing driven by prostaglandin E2
Subhankar Mukhopadhyay1,2, Eva Heinz1, Immacolata Porreca1, Kaur Alasoo1, Amy Yeung1, Huei-Ting Yang3,4, Tobias Schwerd3,5,
Jessica L. Forbester1,6, Christine Hale1, Chukwuma A. Agu1, Yoon Ha Choi1, Julia Rodrigues1, Melania Capitani3, Luke Jostins-Dean7, David C. Thomas8,
Simon Travis3, Daniel Gaffney1, William C. Skarnes1,9, Nicholas Thomson1,10, Holm H. Uhlig3,11, Gordon Dougan1,8, and Fiona Powrie3,7
Loss of IL-10 signaling in macrophages (Mφs) leads to inflammatory bowel disease (IBD). Induced pluripotent stem cells
(iPSCs) were generated from an infantile-onset IBD patient lacking a functional IL10RB gene. Mφs differentiated from IL-
10RB−/− iPSCs lacked IL-10RB mRNA expression, were unable to phosphorylate STAT3, and failed to reduce LPS induced
inflammatory cytokines in the presence of exogenous IL-10. IL-10RB−/− Mφs exhibited a striking defect in their ability to kill
Salmonella enterica serovar Typhimurium, which was rescuable after experimentally introducing functional copies of the IL10RB
gene. Genes involved in synthesis and receptor pathways for eicosanoid prostaglandin E2 (PGE2) were more highly induced in
IL-10RB−/− Mφs, and these Mφs produced higher amounts of PGE2 after LPS stimulation compared with controls.
Furthermore, pharmacological inhibition of PGE2 synthesis and PGE2 receptor blockade enhanced bacterial killing in Mφs.
These results identify a regulatory interaction between IL-10 and PGE2, dysregulation of which may drive aberrant Mφ
activation and impaired host defense contributing to IBD pathogenesis.
Introduction
The inflammatory bowel diseases (IBDs) encompassing Crohn’s
disease and ulcerative colitis are complex chronic inflammatory
conditions of the gastrointestinal tract. Alterations in intestinal
barrier function, host defense, and immune regulation may lead
to aberrant host microbial interactions and chronic intestinal
inflammation (Maloy and Powrie, 2011). Mouse models identi-
fied IL-10 as a critical cytokine in the maintenance of intestinal
homeostasis (Kole and Maloy, 2014; Kühn et al., 1993; Moore
et al., 2001) through limiting the activation state of macro-
phages (Mφs; Bogdan et al., 1991; Smythies et al., 2005). Thus,
mice lacking IL-10 can develop severe and spontaneous enter-
ocolitis (Kühn et al., 1993).
IL-10 signals via a heterodimeric receptor complex of the
IL-10 receptor α (IL10RA) and β (IL10RB), exerting an anti-
inflammatory effect involving phosphorylation of the tran-
scription factor STAT3 (Hutchins et al., 2013; Hutchins et al.,
2012; O’Farrell et al., 1998). Myeloid cell–specific loss of IL-10
receptor α (Shouval et al., 2014a; Zigmond et al., 2014), IL-10
receptor β (Donnelly et al., 2004; Kotenko et al., 1997; Spencer
et al., 1998), or STAT3 (Kobayashi et al., 2003) all lead to
spontaneous colitis in mice, suggesting that IL-10 signaling in
myeloid cells is critical for the maintenance of intestinal ho-
meostasis. In the absence of IL-10 signaling, the resident mi-
crobiota drives excessive MyD88-dependent TLR signaling and
uncontrolled Mφ activation, contributing to intestinal pathology
(Hoshi et al., 2012; Rakoff-Nahoum et al., 2006; Redhu et al.,
2017).
Compelling evidence in support of an involvement of IL-10 in
human intestinal inflammation comes from clinical observations
that rare loss-of-function mutations in the IL10, IL10RA, or
IL10RB genes lead to very-early-onset or infantile IBD with se-
vere phenotypes (Glocker et al., 2010; Glocker et al., 2009;
Glocker et al., 2011; Moran et al., 2013). In addition, IBD genome-
wide association studies (GWAS) have identified common
polymorphisms in the IL-10 pathway as increased risk factors
for adult-onset polygenic IBD (Ellinghaus et al., 2016; Jostins
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et al., 2012). While a protective role of IL-10 is relatively well
established in the context of IBD and other inflammatory dis-
eases (Shouval et al., 2014b), its role in other traits, including
susceptibility to infections is less well understood (Couper et al.,
2008; Peñaloza et al., 2016). Several studies have indicated that
IL-10 protects the host during infection by limiting pathogen-
induced immune pathologies (Couper et al., 2008), but other
studies have shown that IL-10 can directly inhibit microbial
killing by phagocytes (Fleming et al., 1999; Lee et al., 2011;
Oswald et al., 1992), compromising host defense (Redford et al.,
2011). In addition, a range of pathogens has been shown to hijack
the IL-10 pathway to subvert the host immune response (Avdic
et al., 2013; Redpath et al., 2001; Sing et al., 2002a; Sing et al.,
2002b).
To study the impact of IL-10 on the inflammatory and mi-
crobicidal activities of Mφs and how alterations in IL-10 sig-
naling may contribute to IBD, we generated an induced
pluripotent stem cell (iPSC) line from an IBD patient harboring a
homozygous mutation in the IL10RB gene predicted to introduce
a premature stop codon resulting in nonfunctional protein. This
patient’s iPSC-derived Mφs are unresponsive to IL-10 and ex-
hibit a dysregulated inflammatory cytokine response to bacterial
stimuli such as LPS and Salmonella enterica serovar Typhimu-
rium (S. Typhimurium). Despite their hyperactivated pheno-
type, IL-10RB−/−Mφs exhibited a defect in their ability to control
the intracellular growth of S. Typhimurium, a phenotype we
link here to the overproduction of the lipid mediator prosta-
glandin E2 (PGE2). These data identify a novel reciprocal regu-
latory loop between IL-10 and PGE2, active in Mφs, that may
contribute to IBD pathology.
Results
IL-10RB−/− and control Mφs exhibit comparable phenotypes
Skin fibroblasts from a previously reported infantile-onset IBD
patient harboring a homozygous loss-of-function splice site
mutation in the IL10RB gene (Engelhardt et al., 2013) were re-
programmed to induced pluripotency and are henceforth re-
ferred to as IL-10RB−/− iPSCs. As controls, we used four
independent human iPSC lines (HIPSI0114i-kolf_2, HPSI0813-
fpdj_3, HPSI0314i-bubh_1, and HPSI0713i-uimo_1) from unre-
lated healthy individuals obtained from the Human Induced
Pluripotent Stem Cell Initiative (http://www.hipsci.org/; Agu
et al., 2015; Kilpinen et al., 2017). The patient-derived iPSCs
showed normal characteristics when propagated under specific
conditions (Fig. S1). The IL-10RB−/− and the four control iPSC
lines were differentiated into Mφs (Alasoo et al., 2015; Hale
et al., 2015) with very similar phenotypes in terms of mor-
phology and expression of markers. The IL-10RB−/− and control
fpdj_3 Mφs showed comparable surface expression of CD14,
CD16, and CD206 by flow cytometry (Fig. 1 A). Similarly, the WT
and IL-10RB−/− Mφs also displayed an overall comparable global
gene expression profile in the naive state (Fig. 1 B), including
similar levels of mRNA expression for Mφ-associated lineage
markers (CD68 and CSF1R) and transcription factors (SPI1 and
MAFB; Fig. 1 C). The global gene expression was also comparable
betweenWT and IL-10RB−/−Mφs after LPS stimulation (Fig. 1 D),
including comparable increases in mRNA levels of known LPS-
inducible costimulatory molecules (CD40 and CD80) and the
chemokine genes (CXCL3 and CXCL5; Fig. 1 E).
IL-10RB−/− Mφs are unresponsive to IL-10
The patient homozygous splice site mutation IVS311G>C located
in the exon-intron 3 boundary is predicted to be an exon-
skipping variant that leads to a premature stop codon and con-
sequently a truncated, nonfunctional protein (Engelhardt et al.,
2013). This prediction was confirmed by comparing exon read
counts between IL-10RB−/− and control Mφs after RNA se-
quencing (RNASeq). Indeed, significant numbers of reads from
exon 3 were observed in control Mφs, whereas no detectable
exon 3 complementary reads were observed in IL-10RB−/− Mφs
(Fig. 2 A). The quantitative PCR (RT-qPCR) analysis showed a
significantly decreased IL-10RB mRNA expression in the IL-
10RB−/− Mφs compared with control fpdj_3 Mφs or primary
monocyte-derived Mφs obtained from healthy donors (Fig. 2 B),
suggesting that exon 3 skipping may cause mRNA instability
most likely due to nonsense-mediated decay (Brogna and Wen,
2009; Hug et al., 2016). Next, we assessed the impact of the
IL10RB gene mutation on IL-10 signaling. Both IL-10 and IL-6
induce robust phosphorylation of STAT3, but these two cyto-
kines use distinct receptor complexes for intracellular signaling
(Taga and Kishimoto, 1997). Comparison of STAT3 phosphoryl-
ation between control fpdj_3 and IL-10RB−/− Mφs after IL-10 or
IL-6 stimulation by flow cytometry revealed that IL-10 stimu-
lation induced robust STAT3 phosphorylation in control but not
in IL-10RB−/− Mφs. By contrast, IL-6 stimulation induced robust
STAT3 phosphorylation in both control fpdj_3 and IL-10RB−/−
Mφs (Fig. 2 C), suggesting a selective IL-10 signaling defect in IL-
10RB−/− Mφs. Furthermore, both control and IL-10RB−/− Mφs
expressed comparable levels of IL-10RA mRNA (Fig. 2 B), indi-
cating that any IL-10–specific defect in STAT3 phosphorylation
in IL-10RB−/− Mφs was not due to a defect in IL10RA gene ex-
pression. The functional consequences of the mutation were
further investigated by measuring IL-10–mediated suppression
of an LPS-induced inflammatory cytokine response. Exogenous
IL-10 inhibited LPS-mediated TNF-α and IL-6 induction in
control but not in IL-10RB−/− Mφs (Fig. 2 D), consistent with
experiments performed in primary leukocytes from this patient
(Engelhardt et al., 2013). Similarly, the kinetics of cytokine
production between WT fpdj_3 Mφs and IL-10RB−/− Mφs were
compared after exposure to live S. Typhimurium. The IL-
10RB−/− Mφs produced higher amounts of the pro-inflammatory
cytokines IL-8, TNF-α, and IL-6 but also strikingly higher
amounts of IL-10 compared with control fpdj_3 Mφs in a time-
dependent manner (Fig. S2). Again, exogenous IL-10 suppressed
such S. Typhimurium–induced cytokine response in control
Mφs but not in IL-10RB−/− Mφ (Fig. S2).
IL-10RB−/− Mφs are defective in bacterial killing
Next, we investigated whether the loss of IL-10 signaling
impacts microbial killing in IL-10RB−/− Mφs. To assess this, IL-
10RB−/− and control kolf_2 Mφs were infected with S. Typhi-
murium in the presence or absence of exogenous IL-10, and the
amount of intracellular bacteria was assessed by a gentamicin
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protection assay. Consistent with previous reports (Fleming
et al., 1999; Lang et al., 2002b; Lee et al., 2011), we show that
IL-10 pretreatment reduced intracellular killing of S. Typhimu-
rium in control kolf_2 Mφs but not in IL-10RB−/− Mφs (Fig. 3 A).
Unexpectedly, unstimulated IL-10RB−/−Mφs exhibited a striking
defect in bacterial killing compared with control kolf_2 Mφs.
Kinetic analysis showed that this difference was more
prominent between control and IL-10RB−/− Mφs at later time
points (Fig. 3 B). The relative reduction in bacterial killing in IL-
10RB−/− Mφs was also observed when compared with fpdj_3
control Mφs (Fig. S3, A and B). Since the control and IL-10RB−/−
Mφs originated from unrelated individuals, we wanted to ex-
clude the possibility that the observed effect was a consequence
of differences in their genetic background as opposed to a spe-
cific loss of IL-10 signaling. To address this issue, first, a bacterial
killing assay was performed in control Mφs in the presence or
absence of blocking antibodies against IL-10, IL-10RA, or IL-
10RB. Blockade of IL-10/IL-10R signaling significantly reduced
bacterial killing in control Mφs (Fig. S3 C). In addition, we per-
formed genetic complementation of the IL-10RB−/− iPSC line
by introducing a functional copy of the IL10RB gene using a
transcription activator-like effector nuclease (TALEN)–based
Figure 1. IL-10RB−/− Mφs develop normally
and exhibit a normal transcriptional signa-
ture. Mφs were differentiated from IL-10RB−/−
(n = 3) and control iPSCs (n = 4). (A) Surface
expression of CD14, CD16, and CD206 were as-
sessed by flow cytometry. Representative histo-
grams from three independent experiments show
surface expression of antigen in control fpdj_3
(upper panel) and IL-10RB−/− (lower panel) Mφs.
Blue lines indicate specific antibody staining, and
red lines indicate staining by isotype-matched
controls. (B) Average log2FPKM values for all
expressed genes in IL-10RB−/− (n = 3) and control
Mφs (n = 4) were evaluated by RNASeq and are
presented in a scatter plot. (C) Relative mRNA
expression of selected Mφ surface markers
(CD68 and CSF1R) and transcription factors
(MAFB and SPI1) in unstimulated WT (n = 4) and
IL-10RB−/− (n = 3) Mφs are reported as normal-
ized log2TPM values. (D) Genes that are signifi-
cantly induced (red) or repressed (blue) after 6-h
LPS stimulation in bothWT (n = 4) and IL-10RB−/−
(n = 3) Mφs are presented. Genes that show
significantly different expression between control
and IL-10RB−/− Mφs after LPS stimulation are
shown in black. (E) Relative mRNA expression of
selected known LPS-responsive costimulatory
molecules (CD40 and CD80) and chemokine
genes (CXCL2 and CXCL3) were compared be-
tween WT (n = 4) and IL-10RB−/− (n = 3) Mφs
after LPS stimulation, and normalized log2TPM
values are presented. Statistical significance in
B–D was based on FDR <0.05 and fold-change
>2. FPKM, fragment per kilobase million.
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method and designated this line as IL-10RBcomp. Separately, the
IL10RA gene was knocked out (IL-10RA−/−) in the control kolf_2
iPSC line using CRISPR/Cas9 methods (Forbester et al., 2018;
Yeung et al., 2017). The IL-10RBcomp and IL-10RA−/− iPSCs were
differentiated into Mφs and functionally validated in an IL-
10–mediated LPS suppression assay. As expected, IL-10 failed
to suppress LPS-induced IL-6 and TNF-α secretion in IL-10RA−/−
Mφs compared with their isogenic WT controls (Fig. S4 A). By
contrast, exogenous IL-10 suppressed LPS-induced IL-6 and
TNF-α secretion in the IL-10RBcomp Mφs, but not in the original
IL-10RB−/− Mφs (Fig. S4 B). Bacterial killing was assessed in IL-
10RB−/−, IL-10RBcomp, IL-10RA−/−, and control kolf_2 Mφs. IL-
10RA−/− Mφs showed significantly reduced bacterial killing
compared with the isogenic kolf_2 Mφs (Fig. 3 C). Additionally,
defective killing of IL-10RB−/− Mφs was rescued in IL-10RBcomp
Mφs (Fig. 3 D). Considering IL-10 can affect both phagocytic
uptake and intracellular killing within Mφs, we set out to clarify
this issue. Bacterial uptake between IL-10RA−/− and IL-10RB−/−
Mφs and their corresponding isogenic control Mφs was com-
pared after initial incubation with bacteria before adding
gentamicin. No difference in bacterial uptake was observed be-
tween IL-10R–deficient Mφs and their WT controls (Fig. S3 D).
These findings provide strong evidence that the enhanced bac-
terial count observed in IL-10RA−/− and IL-10RB−/− Mφs com-
pared with their controls is due to reduced intracellular killing.
IL-10 modulates subsets of LPS-regulated genes
We compared the transcriptomes of IL-10RB−/− and control Mφs
in the following conditions: (i) unstimulated; (ii) overnight IL-10
stimulation; (iii) 6-h LPS stimulation; and (iv) overnight IL-10
Figure 2. IL-10RB−/− Mφs are unresponsive to IL-10. (A) RNASeq read depth across the IL-10RB gene body plotted for control fpdj_3 (blue) and IL-10RB−/−
(red) Mφs (left panel), with IL10RB gene structure in the panel beneath each plot. The black box indicates the read count from exon 3. The right panel shows
normalized read counts of each of the exons of the IL-10RB gene in WT (n = 4) and IL-10RB−/− (n = 3) Mφs. (B) The relative expressions of IL-10RA and IL-10RB
mRNAwere compared betweenWT (n = 3) and IL-10RB−/− (n = 3) Mφs and monocyte-derivedMφs (MDMs; n = 3) using gene-specific Taqman RT-qPCR probes.
(C) IL-10RB−/− and control fpdj_3 Mφs were stimulated with 20 ng/ml of rhIL-10 or IL-6 for 15 min, and expression of phospho-STAT3 (pY705) was measured
by flow cytometry after staining with a specific antibody. (D) IL-6 and TNF-α levels were measured by ELISA in supernatants of IL-10RB−/− and control kolf_2
Mφs (n = 3) prestimulated overnight with 20 ng/ml rhIL-10 or left unstimulated and then challenged with 2 ng/ml LPS for 6 h in the presence of IL-10. Data in
all panels are representative of at least three independent experiments. Data in B and D are reported as means ± SD of at least triplicate wells of each
condition. Two-way ANOVA with Tukey’s multiple comparisons test was used to assess statistical significance. ***, P < 0.001.
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prestimulation followed by 6-h LPS challenge. With the appli-
cation of principal component (PC) analysis, the first component
(PC1) clearly separated unstimulated and LPS-stimulated control
and IL-10RB−/− Mφs, accounting for ∼39.86% of the variance. By
contrast, IL-10–stimulated samples exhibited an almost identical
expression pattern in both control and IL-10RB−/−Mφs (Fig. 4 A),
indicating that IL-10 by itself did not induce a strong transcrip-
tional response even in WT Mφs. Interestingly, control Mφs
stimulated with IL-10 plus LPS clustered closer to unstimulated
samples, suggesting a partial inhibition of the LPS response by
IL-10. By contrast, IL-10RB−/− Mφs did not show this interme-
diate clustering when stimulated with a combination of IL-10
and LPS (Fig. 4 A), indicating that IL-10 had no obvious effect on
these cells. WT Mφs were separated from each other as well as
from IL-10RB−/− Mφs along PC2, with 22.53% variance irre-
spective of stimulation. This is in part driven by inherent dif-
ferences in genetic background among individual iPSC lines as
well as specific differences in the IL-10RB genotype. Comparison
of the IL-10 response beween WT and IL-10RB−/− Mφs revealed
that only a small number of genes (∼25) were selectively regu-
lated by IL-10 in WT Mφs, and these remained unchanged in IL-
10RB−/− Mφs (Fig. 4 B and Table S3), indicating that IL-10
stimulation alone induced a rather modest transcriptional re-
sponse even in WT Mφs. These IL-10–regulated genes included
SOCS3 and MARCH1 (Fig. 4 B) with known anti-inflammatory
functions (Croker et al., 2003; Galbas et al., 2017; Hunt et al.,
2012; Mittal et al., 2015; Wong et al., 2006). Similarly, WT and IL-
10RB−/−Mφs showed an almost identical transcriptional response
to LPS stimulation with ∼1,050 up-regulated (Table S1) and
∼950 down-regulated genes (Table S2) in both Mφs. Only
∼20 LPS-regulated genes were significantly different between
WT and IL-10RB−/− Mφs, but these also showed the same direc-
tion of regulation. Pathway enrichment analysis of LPS-induced
genes showed significant enrichment of pathways involved in
cytokine signaling, interferons, chemokines, IL-23, and TLR
signaling. Similarly, transcription factor enrichment analysis
of LPS-induced genes revealed significant enrichment of tar-
gets for interferon regulatory factors (IRFs) and NF-κB com-
ponents (Fig. S5 A). By contrast, the LPS down-regulated
genes included Rho GTPases, amino acid and lipid metabolism,
β oxidation pathways, and targets of transcription factors
including SMAD1, FOXO, and PPARγ (Fig. S5 B). Comparison
of LPS-stimulated Mφs with LPS plus IL-10 treatment showed
that IL-10 selectively repressed the expression of ∼29% of LPS
up-regulated genes (Fig. 4 C) and selectively rescued ∼8% of
LPS down-regulated genes (Fig. 4 D) in WT Mφs but had no
effect in IL-10RB−/−Mφs (Fig. 4, C and D), indicating that IL-10
selectively inhibits the LPS transcriptional response in Mφs.
Pathway enrichment analysis indicated an overrepresentation
of transcripts associated with interferon and cytokine signaling
among the LPS-inducible genes that were significantly repressed
by IL-10 in control Mφ (Fig. S5 C). Consistent with this, tran-
scription factor enrichment analysis also showed a significant
enrichment of targets of IRF1, IRF2, IRF7, and IRF8 as well as
these transcription factors themselves, all of which are involved
in Mφ activation and the inflammatory response (Taniguchi
et al., 2001; Fig. S5 C). By contrast, genes that were down-
regulated by LPS but rescued by IL-10 in control Mφs were
overrepresented in pathways related to carbohydrate and lipid
metabolism, suggesting alterations in metabolism. Furthermore,
Figure 3. Loss of IL-10 signaling impairs S.
Typhimurium killing in Mφs. (A) Bacterial
survival measured by gentamicin protection as-
say and reported as CFU/ml in kolf_2 and IL-
10RB−/− Mφs (n = 4) prestimulated with 20 ng/
ml rhIL-10 or left unstimulated and infected with
10 MOI of S. Typhimurium SL1344 (pssaG:GFP);
survival was measured at 5 h. (B) The time
course of S. Typhimurium survival within kolf_2
and IL-10RB−/− Mφs (n = 4) in the presence or
absence of IL-10 is shown. (C) A comparison of
survival of S. Typhimurium between IL-10RA−/−
and control kolf_2 Mφs in the presence or
absence of IL-10 is presented at 5 h. (D) Com-
parison of S. Typhimurium survival/replication
between IL-10RB−/− and IL-10RBcomp Mφs (n =
4). Data shown in all panels are from quadru-
plicate wells, are presented as means ± SD, and
are representative of at least three independent
experiments. Two-way ANOVA with Tukey’s
multiple comparisons test was performed using
GraphPad software to assess statistical signifi-
cance. ***, P < 0.001.
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Figure 4. IL-10 selectively inhibits the LPS-mediated transcriptional response in Mφs. (A) PC analysis (PCA) was performed on all expressed genes in
control Mφs (n = 4) and IL-10RB−/−Mφs (n = 3) stimulated with either 20 ng/ml rhIL-10 (overnight) or 2 ng/ml LPS for 6 h, or IL-10 prestimulation followed by a
6-h LPS stimulation (in the presence of IL-10). (B) Heat maps showing average gene expression levels of ∼25 genes significantly deregulated after IL-10
stimulation in control Mφs (n = 4) but not regulated in IL-10RB−/− Mφs (n = 3; Table S3). (C) Heat maps showing expression levels of selected LPS-induced
genes that are down-regulated in the IL-10 plus LPS condition in control Mφs but remained unchanged in IL-10RB−/− Mφs (IL-10–repressed genes). (D) Heat
maps showing expression levels of selected LPS-repressed genes whose expression was significantly reversed in IL-10 plus LPS treatment in control Mφs but
not in IL-10RB−/− Mφs (IL-10–rescued genes). Only the top most significant genes are presented in C and D (full lists of affected genes are presented in Tables
S4 and S5, respectively). Statistical significance in B–D was based on FDR <0.05 and fold-change >2.
Mukhopadhyay et al. Journal of Experimental Medicine 6
IL-10–mediated regulation of macrophage activation https://doi.org/10.1084/jem.20180649
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/217/2/e20180649/839361/jem
_20180649.pdf by guest on 06 D
ecem
ber 2019
these genes were enriched in targets of the transcription factors
PPARγ (Ricote et al., 1998), LXR (Joseph et al., 2003), and ATF-3
(Gilchrist et al., 2006; Fig. S5 D), known negative regulators of
Mφ activation.
A subset of IBD GWAS candidate genes are regulated by IL-10
in Mφs
Since IL-10 deficiency leads to intestinal inflammation driven
by activated Mφs, we set out to identify the IL-10–regulated
functional gene network that becomes dysregulated in IL-10
deficiency. Consequently, we compared the list of prioritized
gene candidates identified in IBD GWAS (Jostins et al., 2012;
Liu et al., 2015) with a list of 369 IL-10–regulated genes we
identified in Mφs. These include: (i) genes that are selectively
up- or down-regulated by IL-10 stimulation alone in WT Mφs
(Fig. 4 B and Table S3); (ii) LPS-induced genes that are se-
lectively repressed in WT Mφs after IL-10 plus LPS stimula-
tion (Fig. 4 C and Table S4); and (iii) LPS down-regulated
genes that are selectively rescued in WT Mφs after IL-10
plus LPS stimulation (Fig. 4 D and Table S5). We found 21
genes in common between 361 IBD GWAS candidates and our
369 IL-10–regulated genes (Fig. 5 A, Table S6, and Table S7).
Next, we set out to test whether IBD GWAS candidate genes
were significantly enriched among IL-10–repressed genes. We
compared all Mφ-expressed genes with prioritized IBD GWAS
candidates and calculated how many of these IBD candidates
were randomly present (null distribution) among LPS and IL-
10 plus LPS conditions in both WT and IL-10RB−/−Mφs, taking
into consideration the number of differentially expressed
genes in each of these conditions. Next, we calculated the
actual enrichment of IBD candidates in the above conditions
and plotted them on their respective null distribution (Fig. 5
B). The analysis showed that after LPS stimulation, IBD can-
didate genes are significantly enriched among LPS-inducible
genes in both WT and IL-10RB−/− Mφs. However, the number
of up-regulated IBD candidate genes was strikingly reduced in
the IL-10 plus LPS treatment conditions in WT Mφs but not in
IL-10RB−/− Mφs. Genes that were down-regulated by IL-10
during the LPS response were significantly enriched in IBD
GWAS loci (3.26-fold enrichment, P < 1 × 10−4), whereas genes
that were up-regulated by IL-10 during the LPS response
showed no enrichment (0.83-fold, P = 0.709). Thus, these
results identify a subset of prioritized IBD GWAS candidates
that are significantly enriched among LPS-induced genes in
Mφs whose expression is repressed by IL-10 treatment. Next,
we identified all the genes that are predicted to be functionally
connected with the 21 IL-10–regulated IBD candidate genes
(Fig. 5 C) using the InnateDB functional network analysis tool
(Breuer et al., 2013). By comparing which of these network
connections are also regulated by IL-10 in our Mφ RNASeq
analysis, we identified a subnetwork linking IL-10–regulated
GWAS candidates and their functional network connections
that are also regulated by IL-10 in Mφs (Fig. 5 C). Expression
patterns of these subnetwork members in our experimental
conditions revealed LPS-inducible genes that were down-
regulated in the combined IL-10 plus LPS condition (shown
in blue), and LPS-repressed genes that were rescued by
combined treatment (shown in red) in WT Mφs but not in IL-
10RB−/− Mφs. This analysis showed that a number of the IL-
10–regulated IBD GWAS candidate genes and their associated
networks are strongly down-regulated in the WT control Mφs
after combined treatment compared with LPS treatment alone.
These include hub genes such as IRF1 (Kamijo et al., 1994;
Langlais et al., 2016), STAT1 (Kovarik et al., 1998), and JAK2
(Kakar et al., 2005; Okugawa et al., 2003), which are well-known
inflammatory genes and inducers of Mφ activation. By contrast,
only a few targets were up-regulated following IL-10 treatment,
which included known negative regulators of Mφ activation
such as IL-21R (Fabrizi et al., 2014; Fina et al., 2008; Wang et al.,
2016), SOCS3, FCGR1A, and SH2B2. Together, these data identify
an IL-10–regulated core functional module associated with IBD
GWAS genes, which in the absence of IL-10–mediated control
may drive excessive Mφ activation in the context of IBD.
Genes involved in the PGE2 pathway are overexpressed in
IL-10RB−/− Mφs
The IL-10–regulated IBD GWAS functional network included a
phospholipase A2 member PLA2G4A (Fig. 5 C). Phospholi-
pases catalyze the first rate-limiting step in the synthesis of
arachidonic acid–derived eicosanoid lipid mediators including
PGE2 (Fig. 6 A). In addition to PLA2G4A, several other genes in
the eicosanoid pathway such as PTGS2 and PTGER4 have been
identified as potential susceptibility candidates in IBD GWAS,
suggesting a potential role for the PGE2 pathway in intestinal
homeostasis (Liu et al., 2015). We compared the expression
patterns of key genes involved in PGE2 synthesis as well as
PGE2 receptor genes between WT and IL-10RB−/− Mφs using
our transcriptomic data (Fig. 6 B). Only those genes that are
selectively involved in PGE2 biosynthesis and its receptor
pathways were overexpressed in IL-10RB−/− compared with
control Mφs, especially after LPS stimulation (Fig. 6 B, bot-
tom). Strikingly, genes that are involved in the synthesis of
other eicosanoid species were not different between control
and IL-10RB−/− Mφs (Fig. 6 B, top). To independently validate
this data, IL-10RA−/− and its isogenic control kolf_2 Mφs were
stimulated with LPS as before, and expression levels of PTGS1,
PTGS2, PGES, PTGER2, and PTGER4 mRNA were compared by
RT-qPCR. Expression of these PGE2 pathway genes was more
robustly induced in IL-10RA−/− Mφs compared with WT controls
(Fig. 6 C). Taken together, these findings suggest that in the ab-
sence of IL-10 signaling, genes associated with the PGE2 pathway
are more robustly induced in Mφs after LPS stimulation.
IL-10RB−/− Mφs produce higher amounts of PGE2 that limits
their antimicrobial capacity
Next, we directly measured PGE2 levels in cell culture su-
pernatants. IL-10RB−/− Mφs secreted significantly higher
amounts of PGE2 compared with control Mφs after LPS
stimulation (Fig. 7 A), consistent with a previous report that
Mφs from myeloid-specific IL10RA−/− mice produced higher
amounts of PGE2 (Zigmond et al., 2014). Furthermore, IL-10
inhibited LPS-induced PGE2 secretion in control but not in IL-
10RB−/−Mφs (Fig. 7 A), confirming that in the absence of IL-10
signaling, PGE2 production is enhanced. Since previous
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studies suggested PGE2 can compromise the microbicidal ca-
pacity of Mφs (Canetti et al., 2007; Goldmann et al., 2010;
Mittal et al., 2010; O’Brien et al., 2014; Rogers et al., 2014;
Serezani et al., 2007; Serezani et al., 2012), we tested whether
the reduced microbicidal capacity in IL-10RB−/− Mφs is a
consequence of overproduction of PGE2. To this end, we
compared the amount of intracellular S. Typhimurium killing
in WT, IL-10RA−/−, IL-10RB−/−, and IL-10RBcomp Mφs after
pretreatment with two different pharmacological inhibitors
of PGE2 synthesis, aspirin and indomethacin. We show that
both aspirin and indomethacin treatment significantly im-
proved bacterial killing in all Mφ populations (Fig. 7, B and C).
However, aspirin and indomethacin are not selective in-
hibitors of PGE2 synthesis; rather, they block all eicosanoids
by inhibiting PTGS2. Therefore, to show a specific effect of
PGE2 on bacterial killing, we also compared the intracellular
killing of S. Typhimurium in WT and IL-10RA−/− Mφs as well
as IL-10RB−/− and IL-10RBcomp Mφs in the presence of selective
inhibitors of PTGER2 (PF-04418948) and PTGER4 (L-161,982)
either individually or in combination (Fig. 7, D and E). We
show that PTGER2 antagonism had only a modest effect on
bacterial killing, whereas PTGER4 or combined PTGER2 and
PTGER4 inhibition showed the most striking increase in
bacterial killing, indicating a more dominant role of PTGER4
in suppression of bacterial killing, an effect which was most
prominent in IL-10RA−/− and IL-10RB−/− Mφs compared with
control Mφs (Fig. 7, D and E). Taken together, we conclude
that in the absence of IL-10 signaling, PGE2 synthesis is en-
hanced in IL-10RB−/− and IL-10RA−/− Mφs, which in turn re-
duces their microbicidal capacity.
Figure 5. Overlap between IL-10–regulated genes and IBD GWAS candidate genes. (A) Venn diagram between IL-10–regulated genes (red; includes genes
deregulated by IL-10 treatment alone and IL-10–repressed/rescued genes in LPS-stimulated WT control Mφs but unchanged in IL-10RB−/− Mφs) and all the
previously described prioritized gene candidates identified in IBD GWAS (green). (B) Number of IBD GWAS risk loci containing genes up-regulated in various
treatment conditions (solid black circles), in comparison to null distributions generated from gene lists matched for Mφ expression level and gene length
(represented by diamonds showing the region where 95% of null simulations fall). DE, differentially expressed. (C) The 21 overlapping genes identified in A
were used as input for a network analysis in InnateDB with default settings to identify all the genes that are functionally connected with these 21 (not shown).
In this larger network, all genes that are significantly deregulated in control Mφs after combined IL-10 plus LPS stimulation relative to LPS stimulation were
identified and represented as a subnetwork using the Cytoscape visualization tool. The red and blue colors represent up- and down-regulation, respectively, of
genes after combined IL-10 plus LPS treatment compared with LPS stimulation alone. The increase in intensity for each color represents relative levels of up- or
down-regulation compared with LPS stimulation alone. The input IBD candidate genes are shown as diamonds, and their network connections are shown as
circles.
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Discussion
Here, we report a reciprocal regulatory axis between the IL-10
and PGE2 pathways as a key regulator of Mφ activation and
intestinal homeostasis. A delicate balance between these two
pathways is critical for optimal host defense in the absence of
excessiveMφ activation and tissue damage.We show that loss of
IL-10 signaling induces a microbial hyper-responsiveness and
overproduction of PGE2 in Mφs, which in turn limits their
microbicidal capacity. This toxic combination of hyperactive
Mφs and reduced bacterial clearance may fuel chronic intestinal
inflammation as a consequence of IL-10/IL-10R deficiencies.
Mφs differentiated from mutant patient-derived iPSCs
recapitulate the functional defects of primary Mφs (Flynn
et al., 2015; Panicker et al., 2012). The hyperinflammatory
and IL-10–unresponsive phenotype observed in IL-10RB−/−
iPSC-derived Mφ is consistent with similar functional
Figure 6. Loss of IL-10 signaling leads to overexpression of genes involved in the PGE2 pathway. (A) A simplified schematic diagram of the arachidonic
acid pathway from the Kyoto Encyclopedia of Genes and Genomes database showing key steps in the generation of different classes of eicosanoids with a
specific focus on the PGE2 synthesis pathway and its receptors. (B) Heat map showing average expression values of genes involved in PGE2 synthesis and its
receptors (lower panel) and key rate-limiting genes involved in the synthesis of other eicosanoids (upper panel) in IL-10RB−/− (n = 3) and control Mφs (n = 4)
after different treatments. (C) Relative mRNA expression for genes involved in PGE2 synthesis (PTGS2 and PTGES) and PGE2 receptors (PTGER2 and PTGER4)
between IL-10RA−/− Mφs and isogenic control kolf_2 Mφs with or without LPS stimulation analyzed by RT-qPCR. Data from at least triplicate wells of each
condition are presented as means ± SD and are representative of at least three independent experiments. Two-way ANOVAwith Tukey’s multiple comparisons
test was used to assess statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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assays performed using primary leukocytes from that pa-
tient (Engelhardt et al., 2013). Thus, patient-derived and
genome-engineered iPSCs can be used to model specific
aspects of human IBD.
The IL-10RB−/− iPSCs successfully differentiated into Mφs,
suggesting that IL-10 signaling is not critical for iPSC-to-Mφ
differentiation, consistent with previous findings (Lang et al.,
2002a). IL-10RA−/− mice develop intestinal pathology and sys-
temic immune activation at weaning (Redhu et al., 2017), and
bone marrow–derived Mφs from those mice are reported to be
skewed toward a “M1-like” activation state even without stim-
ulation (Shouval et al., 2014a), possibly reflecting inflammatory
conditioning in vivo.We did not detect an overtM1 phenotype in
IL-10RB−/− Mφs, most likely because these cells have not been
exposed to inflammatory preconditioning.
How IL-10 exerts its anti-inflammatory response is not fully
elucidated; our transcriptomic analysis provided some potential
clues that warrant further investigation. IL-10 stimulation alone
affects the expression of only a few genes in control Mφs, in-
cluding SOCS3 (Croker et al., 2003; Wong et al., 2006) and
MARCH1 (Galbas et al., 2017; Hunt et al., 2012; Mittal et al., 2015)
with known anti-inflammatory and Mφ deactivation functions.
However, consistent with previous findings, the IL-10 effect was
most prominent in repression of LPS-induced inflammatory
genes (Gopinathan et al., 2012; Lang et al., 2002a; Murray,
2005), possibly through epigenetic mechanisms (Conaway
et al., 2017; Kobayashi et al., 2012; Simon et al., 2016). In addi-
tion, IL-10 also induced expression of LPS-repressed genes in-
cluding those related to carbohydrate and lipid metabolism, in
linewith a recent report that the anti-inflammatory effects of IL-
10 involve metabolic reprogramming of Mφs (Ip et al., 2017). IL-
10 also rescued LPS-induced suppression of transcription factors
PPARg (Ricote et al., 1998), LXR (Joseph et al., 2003), and ATF-3
(Gilchrist et al., 2006), all of which are involved in regulating the
Mφ inflammatory response.
An intriguing new finding is the enrichment of IBD GWAS
candidates among IL-10-repressed LPS-inducible genes.
Among these are a number of cytokines and transcriptions
factors centered on the IL-12/IL-23 axis and interferon re-
sponse genes, several of which are known to mediate intes-
tinal inflammation (Maloy and Powrie, 2011). Thus, this
network of genes that includes known inflammatory tran-
scription factors JAK2, STAT1, and IRF1 as hub genes and their
transcriptional targets represents an IL-10–regulated functional
Figure 7. Excessive PGE2 production limits
antimicrobial capacity of IL-10RB−/− Mφs. (A)
PGE2 levels measured by ELISA in supernatants
from IL-10RB−/− and control kolf_2 Mφs (n = 4)
prestimulated overnight with 20 ng/ml rhIL-10
or unstimulated (Unstim) and further stimulated
with 2 ng/ml LPS for 6 h in the presence or
absence of IL-10 as appropriate. (B and C)
Bacterial survival measured at a 5-h time point
by gentamicin protection assay and reported as
CFU × 103/ml in IL-10RA−/− Mφs (n = 4) com-
pared with isogenic control kolf_2 Mφs (n = 4; B)
and in IL-10RBcomp Mφs (n = 4) compared with
IL-10RB−/− Mφs (n = 4; C) prestimulated for 2 h
with COX2 inhibitors aspirin (10 µM) or indo-
methacin (10 µM) or left unstimulated and then
infected with 10 MOI of S. Typhimurium SL1344
(pssaG:GFP) in the presence or absence of COX2
inhibitors. (D and E) Bacterial survival as in B
and C in IL-10RA−/− Mφs (n = 4) compared with
isogenic control kolf_2 Mφs (n = 4; D) and in IL-
10RBcomp Mφs (n = 4) compared with IL-10RB−/−
Mφs (n = 4; E) stimulated with 20 nM EP2, EP4,
and EP2 plus EP4 antagonists or left un-
stimulated. In these experiments, inhibitors were
added after initial bacterial uptake. Data shown
in all panels are from at least quadruplicate
wells, are presented as means ± SD, and are
representative of at least three independent
experiments. Two-way ANOVA with Tukey’s
multiple comparisons test was performed using
GraphPad software to assess statistical signifi-
cance. ***, P < 0.001; *, P < 0.05.
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module that when dysregulated in IL-10R–deficient settings may
lead to pathogenic Mφ activation and intestinal inflammation.
Enrichment of IBD GWAS candidates raises the possibility that
alterations in this functional module may be a biomarker and
therapeutic target of deranged Mφ activation in polygenic IBD.
Perhaps the most significant finding of our study is that IL-
10RB−/− and IL-10RA−/− Mφs showed a marked deficiency in
bacterial killing. This is arguably counterintuitive, as IL-10
treatment also reduced bacterial killing in WT Mφs (Fig. 3) as
described by others (Fleming et al., 1999; Lang et al., 2002b; Lee
et al., 2011; Oswald et al., 1992). Thus, IL-10 treatment and IL-10
blockade both compromise the microbicidal capacity of Mφs.We
present evidence that the reduced antibacterial properties of IL-
10R–deficient Mφs is due to enhanced PGE2 secretion. Previous
studies have highlighted a negative feedback loop between IL-10
and PGE2. Thus, PGE2 induced in response to innate immune
stimulation augments IL-10 secretion and signaling (Alvarez
et al., 2009; Cheon et al., 2006; Harizi et al., 2002), which in
turn limits PGE2 secretion in an autocrine fashion (Berg et al.,
2001; MacKenzie et al., 2013; Niiro et al., 1997; Niiro et al., 1994).
Hence, in the absence of IL-10R signaling, the negative regula-
tory arm of this feedback loop is broken, leading to enhanced
secretion of PGE2. Thus, the enhanced IL-10 secretion observed
in IL-10RB−/− Mφs (Fig. S2) could be driven by enhanced PGE2
signaling in these cells. PGE2 excretion is raised in the stools of
patients with ulcerative colitis (Gould, 1975). In untreated pa-
tients with ulcerative colitis in remission and in relapse, mu-
cosal PGE2 release was highly increased compared with controls
(Rampton et al., 1980). Human genetic studies have also iden-
tified a number of genes in the PGE2 pathway as susceptibility
candidates for IBD (Libioulle et al., 2007; Liu et al., 2015). PGE2
blockade by nonsteroidal anti-inflammatory drugs (Lanas,
2009) and monogenic loss of function mutations in PLA2G
lead to early onset and severe intestinal pathologies mimicking
the pathogenic side effects of nonsteroidal anti-inflammatory
drugs (Brooke et al., 2014; Maddirevula et al., 2016). Similarly,
in a murine model, monocyte-derived PGE2 is essential for pro-
tection against immunopathology during acute intestinal infection
(Grainger et al., 2013), suggesting that the PGE2 pathway pro-
motes intestinal homeostasis.
However, the role of PGE2 in inflammation is complex
(Harris et al., 2002). It is generally considered as an inflamma-
tory mediator primarily due to its effect on the vasculature.
However, it also has significant immunoregulatory effects, es-
pecially onmyeloid cells by limiting their inflammatory and host
defense response (Agard et al., 2013; Medeiros et al., 2012).
There are four distinct G protein coupled receptors (EP1-4) for
PGE2. They have distinct tissue distribution, binding affinities,
and signaling specificities that together determine their pro- or
anti-inflamatory functions (Rodr´ıguez et al., 2014). Mφs pre-
dominantly express EP2 and EP4, which limit their host defense
function by inhibiting TLR signaling (Perkins et al., 2018;
Strassmann et al., 1994). PGE2 also influences phagocytic uptake,
oxidative burst, and autophagic killing of cytosolic bacteria
(Canetti et al., 2007; Goldmann et al., 2010; Mart´ınez-Colón
et al., 2018; Mittal et al., 2010; O’Brien et al., 2014; Rogers
et al., 2014; Serezani et al., 2007; Serezani et al., 2012). In
addition, PGE2 also affects Mφ metabolism and associated Mφ
polarization, mitochondria membrane potential, and endoplas-
mic reticulum function (Sanin et al., 2018); these in turn can
influence a multitude of host defense mechanisms inMφs. Many
of these are shown to be particularly important for defense
against S. Typhimurium (Thomas et al., 2017; West et al., 2011).
Thus, we envisage that PGE2 overproduction may have im-
pacted many of these microbicidal mechanisms, resulting in
reduced bacterial killing in IL-10RA−/− and IL-10RB−/− Mφs. In
addition, pharmacological blockade of PGE2 synthesis and its
receptors rescued this phenotype in IL-10RB−/− and IL-10RA−/−
Mφs, further highlighting the pathogenic relevance of the PGE2-
mediated aberrant antimicrobial response in IL-10 signaling
deficiencies. Selective inhibition of EP2 and EP4 revealed their
differential influence on antibacterial mechanisms, with EP4
being more dominant. This is an intriguing new observation
with potential therapeutic implications and warrants further
investigation using genetic approaches to establish the relative
impact of these two receptors on Mφ antimicrobial properties.
IL-10 and PGE2 induce overlapping yet distinct inhibitory
effects on Mφs (Brencicova et al., 2017). Further studies are
required to decipher the relative anti-inflammatory functions of
IL-10 and PGE2 in the intestine. However, clinical studies have
shown that the PGE2 pathway is strongly induced in both pe-
diatric and adult IBD patients, and PGE2 metabolites are reliable
biomarkers of intestinal inflammation (Arai et al., 2014;
Hagiwara et al., 2017), indicating a general involvement of this
pathway in common forms of IBD beyond rare diseases such as
IL-10 deficiency.
In summary, independent clinical and genetic evidence im-
plicates IL-10 and PGE2 pathways in the maintenance of intes-
tinal homeostasis. Here, we connect these two pathways
mechanistically, suggesting that they function as an integrated
regulatory module to control Mφ function and that dysregula-
tion of this balance in the intestine may have important con-
sequences for both host defense against infection andmaintenance
of intestinal homeostasis.
Materials and methods
Patient with IL-10RB mutation
The phenotype and underlying genetic mutation of this
infantile-onset IBD patient have been reported (Engelhardt et al.,
2013). Briefly, the female patient of Arabic origin was born to a
consanguineous marriage. Two siblings died in the first few
months of life due to severe intestinal inflammatory disease. At
the age of 6 mo, the patient developed diarrhea, fever, and
perianal disease. She was treated with steroids. At the age of 9
mo, a subtotal colectomy with an ileostomy was performed, but
perianal disease persisted. Steroids were finally stopped at the
age of 9 yr, but perianal disease persisted. Diverse treatments
with infliximab and methotrexate, certolizumab, and adalimu-
mab controlled neither the colitis nor the perianal disease. The
patient experienced multiple extraintestinal manifestations
including finger sepsis, poor dentition, gum hyperplasia,
chronic paronychia, ulcerated perineum, and hypertrophic
skin. At the age of 12 yr, an EBV lymphoma was diagnosed, and
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chemotherapy was initiated. Genetic analyses revealed a ho-
mozygous splice site mutation in IL10RB gene at nucleotide
IVS3G>C, resulting in exon 3 skipping, frame shift, premature
stop codon, and a predicted truncated IL-10RB protein at
amino acid position 72 (p.Leu59fsX72) that is consistent with
the phenotype of the patient (Engelhardt et al., 2013). Most
recently, she developed a new non-Hodgkin’s lymphoma of
sclerosing type.
Human experimental guidelines approval statement
A favorable ethical opinion was granted by the National Re-
search Ethics Service Research Ethics Committee Yorkshire and
The Humber—Leeds West (UK), reference number 15/YH/0391.
Generation of iPSCs from IL-10RB−/− patient fibroblasts
Reprogramming
A skin biopsy was taken from the patient to generate fibroblasts.
5 × 105 cells were plated in one well of a 6-well plate in fibroblast
growth medium. The next day, the cells were transduced with
Sendai viruses encoding the transcription factors hOCT4,
hSOX2, hKLF4, and hc-MYC using a multiplicity of infection
(MOI) of 3 and then incubated overnight at 37°C in a 5% CO2
incubator. The virus-containing medium was replaced on the
next day with fresh fibroblast growth medium and cultured
further for 4 d in the same medium. Starting from day 5 after
transduction, cells were maintained in iPSC media (knockout
serum replacement plus fibroblast growth factor 2 [FGF2]) and
changed daily. 10–21 d after transduction, the transduced cells
began to form colonies with iPSC morphology, and visible col-
onies were handpicked and transferred onto 12-well inactivated
MEF feeder plates. Colonies were expanded into 6-well MEF-
coated feeder plates and passaged every 5–7 d (depending on
the confluence of the plates) at a desired ratio.
Culture and propagation
To expand colonies, iPSCs were grown on irradiated MEF feeders
(Globalstem) using the stem cell media described below. Advanced
DMEM (Life Technologies) was supplemented as follows: 10%
Knockout Serum Replacement (Life Technologies), 2 mM
L-glutamine (Life Technologies), 0.14% 2-mercaptoethanol (Sigma-
Aldrich), and 4 ng/µl of recombinant human basic FGF2. Media
were changed daily, and the cells were passaged every 7 d de-
pending on the confluence of the plates. Fibroblasts were grown in
media consisting of Advanced DMEM, 10% FBS, 1% pen/strep, 1%
L-glutamine, and 0.07% 2-mercaptoethanol.
Passaging
To passage iPCS, cells were washed with PBS and incubated
with collagenase (Collagenase IV, 1 mg/ml, 17104–019; In-
vitrogen) and dispase (1 mg/ml, 17105–041; Invitrogen) for
45 min. After that, colonies were collected in a falcon tube
containing iPSC media and were allowed to sediment for
2 min. The supernatant, containing residual collagenase/dis-
pase, was removed, and the colonies were washed once with
iPSC medium. The colonies were allowed to sediment again,
and the supernatant was removed. Finally, colonies were
mechanically broken up and plated onto fresh MEF feeders.
Cells were passaged every 5–7 d (depending on the confluence
of the plates) at a desired ratio.
Differentiation of IL-10RB−/− iPSCs into three germ layers
The IL-10RB−/− iPSCs were characterized by assessing their
pluripotency state as well as their ability to differentiate into
three germ layers using methods described previously (Agu
et al., 2015). Briefly, for pluripotency assays, colonies were
grown on MEF feeder plates, and expression levels of pluri-
potency markers OCT4, SOX-2, and NANOG were assessed by
immunohistochemistry. For differentiation into mesoderm, en-
doderm, and neuroectoderm, cells were cultured overnight in
predifferentiation medium CDM-PVA (chemically defined me-
dium with poly venyl alcohol) supplemented with recombinant
Activin-A (10 ng/ml; Cambridge Stem Cell Institute [CSCR],
University of Cambridge) and zebrafish FGF2 (12 ng/ml; CSCR,
University of Cambridge). For differentiation into mesoderm
following culture in predifferentiation media, spent media were
removed and replaced with fresh CDM-PVA medium con-
taining bone morphogenic protein 4 (BMP4, 10 ng/ml; R&D
Systems), FGF2 (20 ng/ml; CSCR, University of Cambridge),
recombinant Activin-A (10 ng/ml; CSCR, University of Cam-
bridge), LY29004 (10 mM; Promega), and CHIR99021 (5 mM;
Selleck Chem) and subsequently cultured for 3 d with daily
media change. Expression of mesodermal marker Bracyury,
Mixl1, and Eomes were determined by immunohistochemis-
try. For differentiation into endoderm, following culture in
predifferentiation media, cells were cultured further in dif-
ferentiation media for 3 d. Briefly, day 1 spent media was
removed and replaced with fresh CDM-PVA medium supple-
mented with recombinant Activin-A (100 ng/ml; CSCR, Uni-
versity of Cambridge), zebrafish FGF2 (80 ng/ml; CSCR,
University of Cambridge), BMP4 (10 ng/ml; R&D Systems),
LY29004 (10 mM), and CHIR99021 (3 mM). Day 2 media were
removed and replaced with fresh CDM-PVA medium supple-
mented with recombinant Activin-A (100 ng/ml), zebrafish
FGF2 (80 ng/ml), BMP4 (10 ng/ml), and LY29004 (10 mM).
Day 3 media was removed and replaced with RPMI medium
supplemented with B27 (13; Life Technologies), recombinant
Activin-A (100 ng/ml), zebrafish FGF2 (80 ng/ml), and Non-
Essential Amino Acids (13; Life Technologies) with daily me-
dia change. Expression of endodermal marker GATA4 was
determined by immunohistochemistry. For differentiation to
neuroectoderm, iPSCs were grown for 12 d in CDM-PVA me-
dium supplemented with SB431542 (10 mM; Tocris Biosci-
ence), FGF2 (12 ng/ml; CSCR, University of Cambridge), and
NOGGIN (150 ng/ml; R&D Systems) with daily media change.
Expression of neuroectoderm marker Nestin1 was determined
by immunohistochemistry.
Genome editing and overexpression experiments
Detailed methods for generating IL-10RA−/− iPSCs by CRISPR/
CAS9-based genome editing in the control kolf_2 line (Yeung
et al., 2017) and complementation of IL-10RB−/− iPSCs by in-
troducing functional copies of IL-10RB gene using a TALEN-
based approach have been previously reported by our group
(Forbester et al., 2018).
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Generation of IL-10RA−/− IPSCs by CRISPR technology
Control kolf_2 cells were adapted to feeder-free culture, and
several sublines were isolated by single-cell cloning. The subline
kolf_2-C1 was used for this study, and these cells showed a
stable, normal karyotype (46; XY) for ≤25 passages. Biallelic
knockouts in kolf_2 human iPSCs were generated using a
method that was found to minimize the potential for off-target
effects. Briefly, the intermediate targeting vector for each gene
was generated by Gibson assembly of the four fragments: puc19
vector, 59 homology arm, R1-pheS/zeo-R2 cassette, and 39 ho-
mology arm. The homology arms were amplified by PCR from
kolf_2 human iPSC genomic DNA. pUC19 vector and R1-pheS/
zeo-R2 cassette were prepared as gel-purified blunt fragments
(EcoRV digested), while the PCR fragments were either gel pu-
rified or column purified (QIAquick; Qiagen). The resultant
Gibson assembly reactions (Gibson Assembly Master Mix; NEB)
were transformed into NEB 5-alpha competent cells, and clones
resistant to carbenicillin (50 µg ml−1) and zeocin (10 µg ml−1)
were analyzed by Sanger sequencing to verify all junctions.
Subsequently, the intermediate targeting vectors were turned
into donor plasmids via a Gateway exchange reaction. LR Clo-
nase II Plus enzyme mix (Invitrogen) was used as described
previously (Tate and Skarnes, 2011), with the difference that it
was a two-way reaction exchanging only the R1-pheSzeo-R2
cassette with the pL1-EF1αPuro-L2 cassette. The latter had
been generated by cloning synthetic DNA fragments of the
EF1α promoter and puromycin into one of the pL1/L2 vectors
as described previously (Tate and Skarnes, 2011). Following
Gateway reaction and selection on YEG + carbenicillin (50 µg
ml−1) agar plates, correct donor plasmids were confirmed by
Sanger sequencing of all junctions. Plasmids carrying single
guide RNA sequences were generated by cloning forward and
reverse strand oligos into the BsaI site of either U6_BsaI_gRNA or
p1260_T7_BsaI_gRNA vectors (kindly provided by Sebastian Gerety,
Wellcome Trust Sanger Institute, Cambridge, UK). Kanamycin-
resistant clones (50 µg ml−1) were isolated, and cloning of the cor-
rect sequence was verified by Sanger sequencing.
Human iPSCs were dissociated to single cells and nucleo-
fected (Amaxa2b nucleofector; Lonza) with Cas9 coding
plasmid (hCas9, 41815; Addgene), single guide RNA plasmid,
and donor plasmid. Following nucleofection, cells were se-
lected for ≤11 d with 0.25 µg ml−1 puromycin. Individual col-
onies were picked into 96-well plates, grown to confluence,
and then replica plated. Once confluent, the replica plates
were frozen as single cells in 96-well vials, or the wells were
lysed for genotyping.
To genotype individual clones from 96-well replica plates,
cells were lysed and used for PCR amplification with LongAmp
Taq DNA Polymerase (NEB). Insertion of the cassette into the
correct locus was confirmed by visualizing on 1% E-gel (Life
Technologies) PCR products generated by gene-specific (GF1 and
GR1) and cassette-specific (ER and PF) primers for both 59 and 39
ends. We also confirmed single integration of the cassette by
performing an RT-qPCR copy number assay. To check the
CRISPR site on the nontargeted allele, PCR products were gen-
erated either from across the locus, using the 59 and the 39 gene-
specific genotyping primers (GF1-GR1), or from around the site
using primers 5F-3R that would amplify a short, ∼500-bp, am-
plicon. In both cases, the PCR products were treated with exo-
nuclease and alkaline phosphatase (NEB) and Sanger sequenced
using primers SF and SR.
Complementation of IL-10RB−/− iPSCs
To restore expression of functional IL10RB gene in the IL-10RB−/−
patient iPSCs, we used the TALEN-mediated gene integration
approach to integrate a functional copy of the IL10RB gene into
the genome of the IL-10RB−/− mutant patient iPSCs. In brief, we
generated the AAVS1 EF1a-IL10RB-PGK-puro targeting vector by
Gibson assembly. We transformed the Gibson assembly product
into OneShot TOP10 chemically competent Escherichia coli
(Thermo Fisher Scientific) and picked positive colonies. We
isolated plasmids from the positive colonies and confirmed the
presence and sequence of EF1α-IL10RB in the targeting vector by
restriction digests, PCR and sequencing. Subsequently, the tar-
geting vector was transformed into competent E. coli to isolate
endotoxin-free plasmids to transform into the IL-10RB−/− patient
iPSCs. We transfected the mutant human iPSCs with TALEN-L
(59-CCCCTCCACCCCACAGT-39), TALEN-R (59-TTTCTGTCACCA
ATCCT-39) and targeting vector via nucleofection (Amaxa Bio-
systems). The resultant targeted cells were selected on pu-
romycin for 7 d. Surviving colonies were picked and
expanded. The positive clones were confirmed by PCR and
sequencing. All iPSC lines used in this study are karyotypi-
cally normal.
Directed differentiation of iPSCs into mature Mφs
The detailed protocol for iPSC-to-Mφ differentiation has been
described (Alasoo et al., 2015; Hale et al., 2015). Briefly, for Mφ
differentiation, iPSC colonies grown on mouse feeders were
detached with collagenase and dispase and transferred into low
adherent bacteriological plastic and cultured for another 3 d
using iPSC base media without FGF2 to form a three-germ layer
containing embryoid bodies. After 3 d, for long-term production
of myeloid precursors, embryoid bodies were transferred into
gelatin-coated tissue culture plastic dishes in X-vivo 15 medium
supplemented with 25 ng/ml IL-3 and 50 ng/ml M-CSF (both
R&D Systems). Terminal differentiation of myeloid precursors
into mature Mφs was achieved by culturing myeloid pre-
cursors in high concentrations of M-CSF (100 ng/ml) in RPMI
medium supplemented with 10% FCS, L-glutamine, penicillin,
and streptomycin.
Bacteria and growth conditions
S. Typhimurium SL1344 harboring the reporter plasmid pssaG::
GFP was grown on L-broth or L-agar containing ampicillin at
100-μg/ml final concentration. S. Typhimurium SL1344(pssaG::
GFP) has been described previously (McKelvie et al., 2004).
Briefly, the promoter region of ssaG was cloned into plasmid
pQF50, upstream of a promoterless GFP gene derived from
pmutGFP3.1 (Promega Laboratories). Growth in conditions fa-
voring the activation of Salmonella Pathogenicity Island-2, of
which pssaG is a component that leads to expression of GFP via
the ssaG promoter region. For the infection studies, we grew
the cultures statically overnight to simulate microaerophilic
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conditions at 37°C. The culture OD at 600 nmwasmeasured, and
the CFU/ml was calculated.
Gentamicin protection assay for assessing bacterial survival
within Mφs
Bacterial uptake, intracellular survival, and replication were
assessed using a gentamicin protection assay as described pre-
viously (Weinstein et al., 1998), with minor modifications.
Briefly, 2 × 105 Mφs were plated on 24-well plates in RPMI
supplemented with 10% heat-inactivated FCS and 2 mM
L-glutamine without antibiotics. As indicated, in some experi-
ments, cells were pretreated overnight with either 20 ng/ml
recombinant human IL-10 (rhIL-10) or 20 µg/ml blocking anti-
bodies against human IL-10 (clone 25209), IL-10RA (clone
37607), or IL-10RB (clone 90220). Antibodies were from R&D
Systems and added for overnight and kept throughout the killing
assay. In some experiments, cells were pretreated for 2 h with
either 10 µM aspirin or indomethacin (two well-known COX2
inhibitors). In some other experiments, we used 20 nM PTGER2
antagonist (PF-04418948) and PTGER4 antagonist (L-161,982),
either individually or in combination. In these experiments,
antagonists were added after initial bacterial uptake to avoid any
potential effect on bacterial uptake. Subsequently, the indicated
MOI of S. Typhimuriumwas added to the medium containing no
antibiotics and incubated at 37°C for 0.5 h to allow bacterial
uptake. Cells were washed three times with PBS and incubated
for an additional 1 h in medium containing 50 µg/ml gentamicin
to kill extracellular bacteria. After incubation, medium was re-
moved and replaced with medium without any antibiotics. After
the indicated time points, cells were lysed in 0.1% Triton X-100
in PBS solution, and multiple 10-fold serial dilutions were plated
on Luria broth agar containing 100 µg/ml ampicillin. The
numbers of intracellular bacteria were determined by counting
colonies the next day.
IL-10 suppression assay and cytokine analysis
Briefly, 1 × 105 Mφs were plated on 96-well plates in RPMI
supplemented with 10% FCS and L-glutamine without anti-
biotics. Some wells were pretreated overnight with 20 ng/ml
rhIL-10. The next day, cells were stimulated with 2.5 ng/ml LPS
for 6 h in the presence or absence of IL-10. After incubation,
supernatants were harvested and stored at −80°C for cytokine
analysis. In some experiments, IL-10–pretreated Mφs were in-
fected with S. Typhimurium (MOI 1) in the presence or absence
of IL-10 as before; after 1 h of incubation, cells were washed
three times with PBS to remove extracellular bacteria, and fresh
medium was added with or without IL-10 as appropriate. After
indicated time points, 25 µl of mediumwas harvested and stored
at −80°C for cytokine analysis and replaced with the same vol-
ume of medium for subsequent time points. Cytokine concen-
trations in LPS-stimulated samples were analyzed by ELISA, and
cytokines from S. Typhimurium–infected supernatants were
analyzed by Luminex assay.
Measurement of PGE2
The PGE2 level in the tissue culture medium was determined
using a commercially available competitive ELISA kit (Abcam)
according to the manufacturer’s instructions. The ELISA-
based PGE2 measurement is a semiquantitative method that
may overestimate absolute levels of PGE2, but accurately re-
flect the relative abundance of PGE2 between different con-
ditions such as WT and IL-10B−/− Mφs in the context of
this study.
Flow cytometry
The IL-10RB−/− and control Mφs were grown in tissue culture
plastic dishes in RPMI medium. Cells were detached using
lidocaine-EDTA solution as described previously (Mukhopadhyay
et al., 2006). Mφs were transferred into 96-well round-bottom
plates at a density of 105 cells/well and incubated for 30 min at
4°C in 100 µl of FACS blocking buffer containing 5% FCS in PBS,
0.1% sodium azide, and 2 µl of Trustain Fc receptor block. After
incubation, 5 µl of directly conjugated anti-human antibodies
against individual Mφ plasma membrane antigens CD14 A488,
CD16 APC-Cy7 (AbD Serotec), and CD206 APC (Becton Dickinson)
or appropriate isotype-matched control antibodies with the same
fluorophore were added to each well and incubated for an addi-
tional 30 min. Cells were washed twice with FACs buffer, re-
suspended in PBS, and analyzed on a Becton Dickinson FACsAria11
using FACS Diva software. For analysis of intracellular phos-
phorylated STAT3, cells were cultured for 15 min with 20 ng/ml
rhIL-10 fixed with BD cytofix and permeabilized with ice-cold BD
permbuffer III stainedwith anti-pSTAT3 (pY705)-Alexa Fluor 647
(clone 4/P-STAT3) according to the manufacturer’s Phosflow
protocol (BD Biosciences). Signals were acquired on a BD LSR
Fortessa (BD Biosciences) with FACS-Diva software (BD Bio-
sciences). Data were analyzed using Flowjo v10.1 software.
RT-qPCR
RNAwas isolated from either iPSC-derivedMφs or from primary
monocyte-derived Mφs with a Qiagen RNAeasy kit and reverse
transcribed with the QuantiTect RT kit (Qiagen) according to the
manufacturer’s protocol. All RT-qPCR experiments were per-
formed with TaqMan gene expression assays and TaqMan gene
expression master mix (Applied Biosystems) on the Applied Bi-
osystems StepOne real-time PCR system. RT-qPCR data were
analyzed via the comparative CT method with GAPDH as an
endogenous control. The following TaqMan probes were used for
the indicated genes: Hs00168754_m1 (PTGER2), Hs00168761_m1
(PTGER4), Hs00153133_m1 (PTGS2), Hs00610420_m1 (PTGES),
and Hs99999905_m1 (GAPDH).
RNASeq experiment and analysis
RNA was extracted with an RNeasy Mini Kit (Qiagen) according
to the manufacturer’s protocol. Standard Illumina poly-A en-
riched libraries were prepared and then sequenced 5-plex on
Illumina HiSeq 2500, generating 20–50 million 75-bp paired-
end reads per sample. Sequencing reads were aligned to the
GRCh38 reference genome with Ensembl 74 annotations using
STAR. Reads overlapping gene annotations were counted using
featureCounts (Liao et al., 2014), and DESeq2 (Love et al., 2014)
was used to identify differentially expressed genes. Genes with
false discovery rate (FDR) <0.05 and fold-change >2 were
identified as differentially expressed. All downstream analysis
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was performed in R (R Development Core Team, 2008), and
ggplot2 (Wickham, 2009) and the base package were used for
figures. Differential expression was assessed using the DESeq
function to retrieve the result tables and filtered according to the
cutoffs as above. Differences in the response of the WT Mφs to
different conditions compared with the IL-10RB−/− Mφs were
assessed. The differential expression between naive and IL-
10–stimulated cells was investigated using the interaction term
from DESeq2, which enables testing if the expression change
(fold change) comparing naive to IL-10 expression levels sig-
nificantly differed between the WT and IL-10RB−/− Mφs. Simi-
larly, we also tested whether WT and IL-10RB−/− Mφs showed
any significant difference in their gene expression changes after
LPS or LPS plus IL10 stimulation. Again, the interaction term
from DESeq2 was used to determine any significant differences
in fold changes in gene expression. Testing for enrichment of
Gene Ontology terms, transcription factor target genes, and
metabolic pathways was performed at the InnateDB web server
using the default conditions (Breuer et al., 2013). For the net-
work analysis, the interactions for the 21 genes of interest were
retrieved from InnateDB, and the network was exported from
the network analyst (Xia et al., 2014). The subnetwork was ex-
tracted, the expression data (differences of WT vs. mutant in the
differential expression between LPS and LPS plus IL10) was
overlayed, and all visualization was performed in Cytoscape.
The prioritized IBD GWAS gene candidates from previously
published studies (Jostins et al., 2012; Liu et al., 2015) were used
to compare our RNASeq datasets. Clustering based on gene ex-
pression profiles was performed using the mfuzz package
(Kumar and Futschik, 2007).
Enrichment of IBD gene loci among IL-10–regulated genes in
Mφs
IBD loci and genes
The list of IBD genes came from all candidate IBD genes impli-
cated by the prioritization techniques described previously (de
Lange et al., 2017; Jostins et al., 2012; Liu et al., 2015). This in-
cludes a total of 361 genes across 165 loci. We also used a smaller
list of high-certainty IBD genes, consisting of any gene in the
previous list that was validated by fine-mapping (de Lange et al.,
2017; Huang et al., 2017), plus genes in loci with only one gene
implicated by multiple prioritization techniques by Jostins et al.
(2012). This list consists of 60 genes across 60 loci.
Calculating the number of IBD loci overlapping a gene list
For a given gene list (e.g., the list of differentially expressed
genes after LPS stimulation), we calculated the number of IBD
loci that contain at least one gene in that gene list. Note that this
number is usually smaller than the number of overlapping
genes, as often multiple coexpressed genes lie within the same
IBD locus.
We compared the number of IBD loci that overlap the gene
list with the distribution of overlaps expected under the null,
calculated by measuring the number of overlapping loci across
10,000 null gene sets (see below). We calculated the enrich-
ment over null expectation (i.e., the ratio of overlapping IBD
loci to the average number of null overlaps in the 10,000 sets),
and a one-tailed P value (the proportion of the 10,000 sets that
had as many, or more, overlaps with IBD loci than the true
value).
Null sets
For each gene set, we generated 10,000 null gene sets that were
matched for gene expression and gene length. To generate each
null set, for each gene in the real gene set, we selected a null gene
uniformly from the set of all genes that were within five per-
centile points of the real gene and added it to the null set. We
excluded both the real genes themselves and previously selected
null genes in the same null set, to produce a list of unique null
genes that did not overlap with the original gene set.
Data availability
RNASeq data are stored in the European Genome-Phenome
Archive under study accession no. EGAS00001001283. Data
will be made available to all researchers upon request to the
Data Access Committee for the Wellcome Trust Sanger Insti-
tute. The restriction on data access is required for human
donor protection.
Online supplemental material
Fig. S1 shows characterization of IL-10RB−/− iPSCs and their
ability to differentiate into three germ layers. Fig. S2 compares
the cytokine response between IL-10RB−/− and Fpdj_3 Mφs in
response to S. Typhimurium infection in the presence or ab-
sence of IL-10. Fig. S3 compares bacterial killing between IL-
10RA−/−, IL-10RB−/−, and corresponding isogenic controls in the
presence or absence of IL-10. Fig. S4 compares the LPS-induced
cytokine response between IL-10RA and kolf_2 as well as IL-
10RB−/− and IL-10RBcomp Mφs in the presence or absence of IL-
10. Fig. S5 shows pathway analysis and transcription factor
enrichment analysis for LPS- and IL-10–regulated genes. Table
S1 shows a list of LPS-inducible genes that are shared between
both WT and IL-10RB−/− Mφs. Table S2 shows a list of
LPS–down-regulated genes that are shared between both WT
and IL-10RB−/−Mφs. Table S3 shows a list of genes up- or down-
regulated by IL-10 stimulation alone in WT Mφs but that re-
main unchanged in IL-10RB−/− Mφs. Table S4 shows a list of
LPS-inducible genes that are repressed by IL-10 in WT but not
in IL-10RB−/−Mφs. Table S5 shows a list of LPS–down-regulated
genes that are rescued by IL-10 in WT but not in IL-10RB−/−
Mφs. Table S6 shows a list of all prioritized gene candidates
from IBD GWAS. Table S7 lists common genes between IBD
GWAS candidates and IL-10–regulated Mφ genes.
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